News

Featured News

7 May 2026

Quantum Motion raises $160m Series C funding round

Quantum Motion, the leading company in silicon transistor-based quantum computing, today announced a $160 million Series C round.
Quantum Computing
Portfolio
8 April 2026

K3 Metrology raises £2.75m Seed funding round

K3 Metrology Ltd (“K3M”), a spin‑out from the National Physical Laboratory (NPL), has launched with a £2.75 million seed investment to commercialise Metralis, a next‑generation, metrology platform designed for advanced manufacturing environments. 
Hardware
Portfolio
2 April 2026

Parkwalk’s Northern Universities Venture Fund makes first two investments

Northern Universities Venture Fund’s first two investments are now complete: Leeds spinout IVFmicro and Manchester spinout Cytotrait.
Funds

More news and updates

7 May 2026

Quantum Motion raises $160m Series C funding round

Quantum Computing
Portfolio
17 April 2026

HealthTech portfolio companies feature in Tech Funding News

Portfolio
8 April 2026

K3 Metrology raises £2.75m Seed funding round

Hardware
Portfolio
2 April 2026

Parkwalk’s Northern Universities Venture Fund makes first two investments

Funds
31 March 2026

Semarion secures $3.8m funding

Life Sciences
Portfolio
30 March 2026

Echopoint secures $2.5m funding

Digital Health MedTech
Portfolio
20 March 2026

With IHT and EIS reform, 2026 is a transitional year

Parkwalk
16 March 2026

Densix raises $4m Seed funding round

Portfolio
6 March 2026

Latest investment in Gripable

Digital Health MedTech
Portfolio
4 March 2026

Oxa raises $103m in Series D funding round

Future Mobility
Portfolio
25 February 2026

FT Adviser – The scale-up shift: What’s changing with EIS?

Parkwalk
25 February 2026

Brainomix extends Series C financing to $25.4m

Digital Health MedTech
Portfolio

The products shown on this website will place your capital at risk and investors may not get back the full amount invested. Past performance may not be repeated and is not indicative of future results.

Parkwalk funds invest in smaller and unquoted companies which carry a higher risk than many other forms of investment. There is no guarantee that target returns will be achieved. There is no liquid market for shares in unquoted companies and there can be difficulties, in valuing and disposing of investments in such companies. Tax reliefs will depend on the investors’ individual circumstance and are subject to change.

Parkwalk does not provide investment or tax advice, and the information on this website should not be construed as such. Parkwalk recommends investors seek advice from a regulated financial adviser that specialises in EIS fund investments before making an investment decision. An investment into any of the funds managed by Parkwalk may only be made on the basis of the information set out in the Information Memorandum and Key Information Document.

The information on this website is directed at United Kingdom residents only. Please confirm you have read this warning and are happy to proceed.